NR4A1 and malignant colon neoplasm: In this study we have investigated the anticancer activity of piperlongumine, a well-known ROS-inducing anticancer agent (Kung et al., 2021; Pan et al., 2022) and show for the first time that this compound is an NR4A1 ligand acting as an inverse agonist in colon cancer cells.